Expertise in
7
conditions

Si Y. Song

Seoul, KR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Seoul, KR 

Overview

Si Song practices practicing medicine in Seoul, Republic of Korea.

Mr. Song is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, Osteotomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 270 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Seoul, Republic of Korea
Other Locations
Gyeonggi-do, Republic of Korea
Hwasong, Republic of Korea
Department Of Otorhinolaryngology Head And Neck Surgery, Daegu, Republic of Korea
Republic of Korea
Gwangju, Republic of Korea
Hwasun, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination with Gemcitabine in Patient with Locally Advanced or Metastatic Pancreatic Cancer
A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination with Gemcitabine in Patient with Locally Advanced or Metastatic Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: March 10, 2025
Intervention Type: Combination product, Drug
Study Drugs: BEY1107, Gemcitabine
Study Phase: Phase 1/Phase 2

270 Total Publications

Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057].
Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057].
Journal: ESMO open
Published: March 11, 2026

Frequently Asked Questions about Si Y. Song

Is Si Y. Song a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Si Y. Song is classified as an Distinguished expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Si Y. Song participate in research or clinical trials?

Yes. Si Y. Song has published 270 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Si Y. Song's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Song's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile